How is AI starting to transform biopharma partnering?
Reserve your seat
Artificial computer intelligence is unlocking vast potential in the development of new medicines and the treatment of myriad illnesses.
On this webinar, we will review where AI is starting to help biopharma companies advance their BD, R&D, and partnering operations, with a focus on competitive intelligence, landscaping, asset identification, and monitoring.
A live Q&A will follow presentations from product leads at Inpart and Patsnap, working in a new strategic partnership to develop AI-enabled platforms that extract maximum value from every breakthrough and collaboration.
Panelists
On this webinar, we will review:
- How AI is staring to impact BD, R&D and partnering
- Opportunities and gains with competitive intelligence
- Where advances in AI are taking shape across the pipeline
- Challenges, limitations and risks of using AI
- Actionable recommendations for AI development programs
About Inpart:
Inpart enables partnering teams to connect, evaluate and execute more efficiently, integrating fragmented data into actionable insights and empowering teams with operational excellence. Inpart's partnering platforms are the preferred choice for more than 6,500 companies, including 90% of the top 50 pharma,and over 250 of the world’s leading academic institutes.
About Patsnap:
Patsnap connects the world’s largest proprietary innovation dataset with next-generation AI to accelerate R&D, IP, materials, and drug discovery. Patsnap’s platforms empower R&D and IP teams to unlock insights, accelerate discoveries, and protect breakthroughs with unprecedented speed and precision.